New opportunities to optimize antithrombotic therapy for secondary stroke prevention

被引:5
|
作者
Kim, Anthony S. [1 ]
Easton, J. Donald [1 ]
机构
[1] UCSF, Dept Neurol, San Francisco, CA USA
关键词
Stroke prevention; secondary stroke prevention; antithrombotic; antiplatelet; clopidogrel; ticagrelor; aspirin; transient ischemic attack; MINOR STROKE; ASPIRIN; CLOPIDOGREL;
D O I
10.1177/1747493019828548
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Stroke symptoms can be unsettling, even when symptoms resolve, but focusing on stroke prevention can be empowering provided that effective interventions for appropriate patient populations are available. Current options include interventions for symptomatic carotid artery stenosis, anticoagulation for atrial fibrillation, high-dose statins, new oral anticoagulants, new developments in atrial fibrillation detection, and new therapeutics are in development. For antiplatelet therapy, aspirin monotherapy is effective but dual antiplatelet therapy with the combination of aspirin and clopidogrel increases hemorrhage risks over the long term that outweigh potential benefits. In the short term though, both the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trials have shown a benefit of short-term dual-antiplatelet therapy, though the increased major hemorrhage risk seen in POINT could justify applying dual-antiplatelet therapy to just the first 21 days. Furthermore, since clopidogrel is a prodrug that must be metabolized to have antiplatelet activity, it is not surprising that the treatment effect in CHANCE was limited to patients who were not carriers of loss-of-function alleles for clopidogrel metabolism. Ticagrelor, an antiplatelet agent which failed to meet its primary endpoint as monotherapy compared to aspirin in the Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial, is currently being tested as combination therapy with aspirin compared to aspirin alone in Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES). These developments along with improvements to the infrastructure to perform rapid evaluations and to apply intensive secondary stroke prevention interventions hold continued promise for the future.
引用
收藏
页码:220 / 222
页数:3
相关论文
共 50 条
  • [41] Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure
    Lusk, Jay B.
    Xu, Haolin
    Peterson, Eric D.
    Bhatt, Deepak L.
    Fonarow, Gregg C.
    Smith, Eric E.
    Matsouaka, Roland
    Schwamm, Lee H.
    Xian, Ying
    STROKE, 2021, 52 (12) : E777 - E781
  • [42] ANTITHROMBOTIC THERAPY FOR CEREBROVASCULAR-DISEASE - PREVENTION AND TREATMENT OF STROKE
    FOSTER, JW
    HART, RG
    POSTGRADUATE MEDICINE, 1986, 80 (08) : 199 - 206
  • [43] Antithrombotic therapy for stroke prevention in patients with atrial fibrillation in Japan
    Maruhashi, Tatsuya
    Higashi, Yukihito
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (17) : 2115 - 2124
  • [44] Extended antithrombotic therapy in secondary prevention: "There is no such thing as a free lunch"
    Costa, Marco
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2020, 39 (09) : 503 - 504
  • [45] Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease
    Capodanno, Davide
    Alberts, Mark
    Angiolillo, Dominick J.
    NATURE REVIEWS CARDIOLOGY, 2016, 13 (10) : 609 - 622
  • [46] Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease
    Davide Capodanno
    Mark Alberts
    Dominick J. Angiolillo
    Nature Reviews Cardiology, 2016, 13 : 609 - 622
  • [47] Antithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy
    Raul Altman
    Thrombosis Journal, 5 (1)
  • [48] Amino Terminal Pro-B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy
    Longstreth, W. T., Jr.
    Kronmal, Richard A.
    Thompson, John L. P.
    Christenson, Robert H.
    Levine, Steven R.
    Gross, Rebecca
    Brey, Robin L.
    Buchsbaum, Richard
    Elkind, Mitchell S. V.
    Tirschwell, David L.
    Seliger, Stephen L.
    Mohr, J. P.
    deFilippi, Christopher R.
    STROKE, 2013, 44 (03) : 714 - 719
  • [49] Amino Terminal Pro-B-Type Natriuretic Peptide, Secondary Stroke Prevention, and Choice of Antithrombotic Therapy
    Elkind, Mitchell
    Longstreth, W. T.
    Kronmal, Richard
    Thompson, John
    Christenson, Robert
    Levine, Steven
    Gross, Rebecca
    Brey, Robin
    Buchsbaum, Richard
    Tirschwell, David
    Seliger, Stephen
    Mohr, J.
    deFilippi, Christopher
    NEUROLOGY, 2013, 80
  • [50] Antithrombotic Therapy for Secondary Prevention in Patients with Non-Cardioembolic Stroke or Transient Ischemic Attack: A Systematic Review
    Tornyos, Daniel
    Balint, Alexandra
    Kupo, Peter
    El Abdallaoui, Oumaima El Alaoui
    Komocsi, Andras
    LIFE-BASEL, 2021, 11 (05):